Share warrant program fully subscribed

XVIVO Perfusion AB's share warrant program 2016/2018 is fully subscribed. A total of 212,000 warrants with the right to subscribe for new shares were issued. Each warrant has in June 2018 the right to subscribe for one new share at a price of SEK 90.22.

The annual shareholder meeting May 3, 2016 approved the warrant program of a maximum of 212,000 warrants to be offered to employees in XVIVO Perfusion. Upon full exercise of the warrants, the share capital increase is around SEK 5,500 corresponding to a dilution of about 0.9 percent of the total number of shares and votes.

Magnus Nilsson, CEO of XVIVO Perfusion: “The broad support is very encouraging and it gives all of our employees a stronger shareholder interest and an even stronger incentive to fulfill our goals.”

July 8, 2016 
XVIVO Perfusion AB (publ)

For further information please contact:

Christoffer Rosenblad, CFO, +1 720 616 2101,
For further information on XVIVO Perfusion’s business, please refer to the company’s website,

The information was submitted for publication on July 8, 2016 at 8:30 a.m.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.


XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in Ludn, Sweden and one office in Denver, the USA. The XVIVO share is listed on NASDAQ First North premier and has the ticker symbol XVIVO. More information can be found on the website The Certified Adviser is Redeye,

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: Website:



Documents & Links